A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients

PHASE4CompletedINTERVENTIONAL

Enrollment

228

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Renal Transplantation

Interventions

DRUG

Everolimus (RAD001)

DRUG

Tacrolimus

DRUG

Basiliximab

DRUG

Corticosteroids

Trial Locations (1)

Novartis, Basel